CSMO 2014 :晚期非小细胞肺癌中医综合治疗方案

2014-07-09 中国中医科学院广安门医院 花宝金 医学论坛网

在7月4日的第八届中国肿瘤内科大会会上,中国中医科学院广安门医院的花宝金教授介绍了晚期非小细胞肺癌中医综合治疗的方案。 花宝金教授的课题组在国家“六五~十五”攻关课题的回顾性研究基础上,形成以辨证论治为纲的晚期非小细胞肺癌中医综合治疗方案草案;以542例ⅢA~Ⅳ期非小细胞肺癌带瘤患者为研究对象,采用前瞻性队列研究的方法对该方案进行适用及验证。研究结果表明该方案治疗晚期非小细胞肺癌具有减轻放化疗毒

在7月4日的第八届中国肿瘤内科大会会上,中国中医科学院广安门医院的花宝金教授介绍了晚期非小细胞肺癌中医综合治疗的方案。

花宝金教授的课题组在国家“六五~十五”攻关课题的回顾性研究基础上,形成以辨证论治为纲的晚期非小细胞肺癌中医综合治疗方案草案;以542例ⅢA~Ⅳ期非小细胞肺癌带瘤患者为研究对象,采用前瞻性队列研究的方法对该方案进行适用及验证。研究结果表明该方案治疗晚期非小细胞肺癌具有减轻放化疗毒副反应,改善临床症状,提高患者生活质量,延长生存期的作用,获得了高水平的循证医学证据。研究结论实现了晚期非小细胞肺癌中医综合治疗方案的整合优化;初步建立了体现中医综合治疗特色的临床疗效评价方法;实现了预防为主,重点前移的预期目标;体现了以辨证论治为治则,最大限度的突出中医特色的理念与构想。

本课题采用前瞻性队列研究的科研设计,分为中医参与的综合治疗队列(包括中医队列和中西医结合队列)、西医队列,旨在获得体现我国目前诊疗水平的晚期非小细胞肺癌中医综合治疗方案与疗效评价方法。本研究中医治疗不限于一方一药,而是以辨证论治为基础,治疗法则为核心,最大程度地减少对治疗措施的限定,充分体现中医辨证论治的思想及中医药治疗疾病的临床特点,有利于真实客观地评价中医药的临床疗效,为探索中医药治疗晚期非小细胞肺癌疗效评价方法进行了有益的尝试,并获得了喜人的成果。

1.初步建立了体现中医综合治疗特色的临床疗效评价方法

中医药治疗肺癌疗效的评价终点是使患者如何获得最大益处,即在满意的生活质量和较长的生存时间基础上取得最大限度的肿瘤缓解率,而不是单纯强调瘤体缩小、消退及无瘤生存时间。总体而言,“带瘤生存”和生活质量的提高是中医中药治疗肺癌疗效有别于当前西医治疗的显著特征。

2. 实现了预防为主,重点前移的预期目标

我们采用中医药综合治疗的方法提前干预,配合放化疗减少减轻了恶心、呕吐等消化道毒副反应,减少肿瘤转移复发,充分发挥重点前移,丰富了中医肿瘤预防为主的科学内涵。

体现了以辨证论治为治则,最大限度的突出中医特色的理念与构想

本次研究我们以辨证论治为基础,选择相应的主方和成药,最大限度的发挥了中医特色,提高了中医治疗的疗效。我们根据专家论证的意见,制定了以下主要治则:化疗患者主要治则:健脾和胃,益气养血,滋补肝肾;放疗患者主要治则:养阴生津、活血解毒、凉补气血;晚期患者主要治则:益气养血,解毒散结为主结合辨证论治。研究结果亦揭示了本次研究制定的中医综合治疗方案的科学性与先进性。

解决的关键技术问题:晚期非小细胞肺癌中医综合治疗方案的整合优化

非小细胞肺癌中医规范化综合治疗方案目的是为中医治疗肺癌提供一套系统的、成熟的治疗策略,为在临床实践中为有序诊疗奠定良好的基础,使治疗获得更好的效果和减少费用。综合治疗方案的制定过程中,既往的研究如何整合优化,既要注重科学性、可重复性,又要具有可操作性并要保持一定的灵活性,是本课题面临的科研技术难题。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=17130, encodeId=68081e1302e, content=x收获很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 22:42:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024712, encodeId=bda42024e1299, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Apr 06 13:10:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059473, encodeId=dcad20594e3de, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 15 02:10:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904944, encodeId=867f190494483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun May 24 20:10:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646835, encodeId=e570164683528, content=<a href='/topic/show?id=91cfe913977' target=_blank style='color:#2F92EE;'>#综合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79139, encryptionId=91cfe913977, topicName=综合治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=690523366225, createdName=zhaohui6739, createdTime=Sun Jan 25 07:10:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    x收获很好的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=17130, encodeId=68081e1302e, content=x收获很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 22:42:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024712, encodeId=bda42024e1299, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Apr 06 13:10:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059473, encodeId=dcad20594e3de, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 15 02:10:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904944, encodeId=867f190494483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun May 24 20:10:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646835, encodeId=e570164683528, content=<a href='/topic/show?id=91cfe913977' target=_blank style='color:#2F92EE;'>#综合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79139, encryptionId=91cfe913977, topicName=综合治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=690523366225, createdName=zhaohui6739, createdTime=Sun Jan 25 07:10:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
    2015-04-06 liuhuangbo
  3. [GetPortalCommentsPageByObjectIdResponse(id=17130, encodeId=68081e1302e, content=x收获很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 22:42:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024712, encodeId=bda42024e1299, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Apr 06 13:10:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059473, encodeId=dcad20594e3de, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 15 02:10:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904944, encodeId=867f190494483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun May 24 20:10:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646835, encodeId=e570164683528, content=<a href='/topic/show?id=91cfe913977' target=_blank style='color:#2F92EE;'>#综合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79139, encryptionId=91cfe913977, topicName=综合治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=690523366225, createdName=zhaohui6739, createdTime=Sun Jan 25 07:10:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=17130, encodeId=68081e1302e, content=x收获很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 22:42:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024712, encodeId=bda42024e1299, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Apr 06 13:10:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059473, encodeId=dcad20594e3de, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 15 02:10:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904944, encodeId=867f190494483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun May 24 20:10:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646835, encodeId=e570164683528, content=<a href='/topic/show?id=91cfe913977' target=_blank style='color:#2F92EE;'>#综合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79139, encryptionId=91cfe913977, topicName=综合治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=690523366225, createdName=zhaohui6739, createdTime=Sun Jan 25 07:10:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=17130, encodeId=68081e1302e, content=x收获很好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 22:42:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024712, encodeId=bda42024e1299, content=<a href='/topic/show?id=c27516459de' target=_blank style='color:#2F92EE;'>#SMO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16459, encryptionId=c27516459de, topicName=SMO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Apr 06 13:10:00 CST 2015, time=2015-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059473, encodeId=dcad20594e3de, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Oct 15 02:10:00 CST 2014, time=2014-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904944, encodeId=867f190494483, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun May 24 20:10:00 CST 2015, time=2015-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646835, encodeId=e570164683528, content=<a href='/topic/show?id=91cfe913977' target=_blank style='color:#2F92EE;'>#综合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79139, encryptionId=91cfe913977, topicName=综合治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=690523366225, createdName=zhaohui6739, createdTime=Sun Jan 25 07:10:00 CST 2015, time=2015-01-25, status=1, ipAttribution=)]

相关资讯

ASCO 2014:克唑替尼一线治疗经选择的NSCLC的PFS显著优于标准化疗

题目:在晚期ALK阳性非鳞NSCLC患者中克唑替尼与培美曲塞+顺铂/卡铂一线治疗的对比:PROFILE 1014 Ⅲ期研究结果 First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients with advanced ALK-positive non-squamous non

ASCO 2014:口服ceritinib治疗ALK阳性NSCLC疗效可观

题目:Ceritinib用于ALK重排(ALK+)晚期非小细胞肺癌(NSCLC):ASCEND-1研究的结果 Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

ASCO 2014:5种单药治疗中国非小细胞肺癌患者II期临床群集试验

摘要号:#TPS8122 第一作者:周清,广东省人民医院肿瘤内科 标题:AUY922, BYL719, INC280, LDK378, 和 MEK162等单药治疗中国非小细胞肺癌患者II期临床群集试验 背景:晚期非小细胞肺癌(NSCLC)的管理治疗已走向个体化肿瘤表型(基于特异的肿瘤发生因素)治疗方向。大多数具有分子特征的肺腺瘤患者都可能从靶向治疗中获益。本试

分析pIII期非小细胞肺癌中miR-155的表达与预后的关系

miR-155高表达不利于手术切除的pIII期非小细胞肺癌(non-small cell lung cancer, NSCLC)的总体生存,并且与淋巴结转移度正相关。MiR-155可作为评价pIII期NSCLC预后的生物标志物。该研究结果发表于《中国肺癌杂志》2014年第5期上。 pIII期NSCLC患者5年生存率低于25%,需要寻找新的预后标志物,指导患者个体化治疗。MiR-155在许多肿瘤中

Lancet:非小细胞肺癌术前化疗 个体受试者资料的系统回顾及荟萃分析

背 景:个体受试者数据荟萃分析证实,术后化疗可提高非小细胞肺癌(NSCLC)患者的存活率。本研究旨在开展个体受试者数据系统回顾及荟萃分析以明确术前化疗在可手术切除的NSCLC患者中的效应。方 法:系统性检索了1965年1月后开展的试验,集中收集了最新的个体受试者资料并对其进行了核对和分析。采用两阶段固定效应模型将单项随机对照试验(包括已发表和未发表的)结果进行合并。本试验的主要结局——总体存活期,

JCI:科学家揭示肺癌内在耐药性发生的分子机制

40%的肺癌患者都不会对阻断肿瘤生长的靶向性疗法产生反应,这也是临床医生们长期以来比较疑惑的一个问题,近日,来自乔治敦大学癌症中心等处的研究人员通过研究揭示了肺癌内在性耐药发生的原因,并且为开发新型药物来逆转这种肺癌耐药性提供了一定的思路,相关研究成果刊登于国际杂志the Journal of Clinical Investigation上。【原文下载】 这项研究中,研究者发现生